Clinical Trial Update: Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial evaluating multiparametric MRI-guided high-dose adaptive radiotherapy with concurrent temozolomide for newly diagnosed Glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Temozolomide (Temozolomide)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING